Nicholas Cozzi

December 19, 2018 -

Sorry, but you do not have permission to view this content.
    References
  1. Cozzi NV. PHARMACOLOGICAL STUDIES OF SOME PSYCHOACTIVE PHENYLALKYLAMINES: ENTACTOGENS, HALLUCINOGENS, AND ANORECTICS. 1994. https://www.researchgate.net/profile/Nicholas_Cozzi/publication/44389571_Pharmacological_studies_of_some_psychoactive_phenylalkylamines_entactogens_hallucinogens_and_anorectics/links/53f492ce0cf22be01c3ecf73.pdf.
  2. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator. Science. 2009;323(5916):934-937. doi:10.1126/science.1166127
  3. Baumann MH, Jr MAA, Partilla JS, et al. The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue. Neuropsychopharmacology. 2012;37(5):1192-1203. doi:10.1038/npp.2011.304
  4. Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogs of 3, 4-(methylenedioxy) amphetamine. Journal of medicinal chemistry. 1993;36(23):3700-3706.
  5. Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3, 4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology. 2013;38(4):552.
  6. Cozzi NV, Sievert MK, Shulgin AT, Jacob III P, Ruoho AE. Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. European Journal of Pharmacology. 1999;381(1):63-69. doi:10.1016/S0014-2999(99)00538-5
  7. Cozzi NV, Gopalakrishnan A, Anderson LL, et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm. 2009;116(12):1591. doi:10.1007/s00702-009-0308-8
  8. Schindler CW, Thorndike EB, Goldberg SR, et al. Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats. Psychopharmacology. 2016;233(10):1981-1990. doi:10.1007/s00213-015-4057-0
  9. Cozzi NV, Nicholas DE. 5-HT2A receptor antagonists inhibit potassium-stimulated γ-aminobutyric acid release in rat frontal cortex. European Journal of Pharmacology. 1996;309(1):25-31. doi:10.1016/0014-2999(96)00325-1
  10. Foley KF, Cozzi NV. Novel aminopropiophenones as potential antidepressants. Drug Development Research. 2003;60(4):252-260. doi:10.1002/ddr.10297
  11. Nicholas CR, Henriquez KM, Gassman MC, et al. High dose psilocybin is associated with positive subjective effects in healthy volunteers. J Psychopharmacol. 2018;32(7):770-778. doi:10.1177/0269881118780713
  12. Brown RT, Nicholas CR, Cozzi NV, et al. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017;56(12):1543-1554. doi:10.1007/s40262-017-0540-6
  13. Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL. Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs. Neuropharmacology. February 2018. doi:10.1016/j.neuropharm.2018.02.028